Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.

Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI0abdd195e81a43d9ac0c44fe9d789f86. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.


These press releases may also interest you

at 11:42
Grupo Casas Bahia announces agreement with partner banks and accelerates Transformation Plan
Grupo Casas Bahia has just closed an agreement with their main creditors, Bradesco and Banco do Brasil, which will preserve R$4.3 billion in cash reserves until 2027, of which R$1.5 billion just in 2024. The agreement includes a grace period of 24...

at 11:41
Whistleblower Law Collaborative Spring Update
Whistleblower Law Collaborative LLC is now representing whistleblowers in emerging new practice areas including cryptocurrency fraud, anti-money laundering and sanctions evasion, and cybersecurity fraud. The award-winning Boston based firm...

at 11:40
Woman-Owned Intellectual Property Firm Begins Second Decade with Rebrand to SGIP
As the number of women-owned employers in the U.S. surges, the woman-owned Law Office of Stacy J. Grossman PLLC is celebrating its 10th anniversary by rebranding as SGIP. The boutique's founder, Stacy Grossman, said that 100% of the firm's lawyers...

at 11:39
Landmark Properties Acquires Pointe on Rio in Austin, Texas
Landmark Properties, a fully-integrated real estate firm specializing in development, construction, investment management, and operation of high-quality residential communities, has acquired Pointe on Rio in Austin, Texas. Pointe on Rio, soon to be...

at 11:39
X- Silicon Announces a NEW Low-Power Open-Standard Vulkan-Enabled C-GPUtm - a RISC-V Vector CPU Infused with GPU ISA and AI/ML acceleration in a Single Processor Core
X-Silicon Inc (XSI), a San Diego-based startup, announced today their new NanoTile open-standard low-power "C-GPU" architecture...

at 11:36
An Evolved Business Purpose For A Transformed Regal Rexnord
Regal Rexnord Corporation announced today an evolved business purpose that reflects its strategic portfolio transformation over the last few years ? now complete, after closing yesterday on the sale of the Industrial Motors and Generators businesses...

More news about Business...


News published on and distributed by: